TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to add a warning about a potential increased risk of the rare eye condition NAION. The agency advises patients to seek prompt medical attention for sudden vision changes and recommends clinicians refer suspected cases to an ophthalmologist.
The U.S. Food and Drug Administration is requiring application holders for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the drugs’ Warnings and Precautions labeling. NAION is rare but can cause sudden, painless vision loss in one eye, sometimes permanently, the agency said.
The FDA’s safety communication says the label change applies to all GLP-1 RA medications. It calls for information about a potential increased risk of NAION, rather than stating that the medicines have been proven to cause the condition. The agency is advising patients, caregivers and health professionals to be alert to sudden vision symptoms in people taking these drugs.
Symptoms listed by the FDA include sudden, painless loss of vision in one eye, which a person may notice on waking; blurred or missing areas of vision, such as blind spots or tunnel vision; distorted color perception; and reduced sharpness in the center of vision. Patients experiencing these symptoms should contact a health professional right away, according to the agency.
For clinicians, the FDA recommends that patients be told to report sudden vision loss, visual-field deficits or other visual disturbances in one eye immediately. If NAION is suspected, clinicians should promptly refer the patient to an ophthalmologist for evaluation. The agency says clinicians should consider discontinuing the GLP-1 RA in patients who develop NAION unless the benefits of treatment clearly outweigh the risk.
Vision Symptoms Need Prompt Attention
The alert advises patients and prescribers to recognize sudden vision changes and seek prompt evaluation. NAION involves reduced blood flow to the front of the optic nerve, according to the FDA, and can result in permanent vision loss. The agency says that when NAION occurs in one eye, the risk of it occurring in the other eye is increased.
GLP-1 RAs are used to treat type 2 diabetes and to reduce excess body weight and maintain weight reduction over the long term. Adding the potential risk to product labeling makes the information available in prescribing and patient materials across the drug class. The guidance does not tell every patient to stop treatment; decisions about continuing or discontinuing medication should be discussed with a health professional, particularly after a suspected or diagnosed NAION event.
The notice distinguishes between a possible medication-associated risk and a confirmed cause in an individual case. Its recommendations focus on awareness, prompt assessment and weighing treatment benefits against risks if NAION develops. Patients should consult a health professional before changing or stopping a prescribed medicine.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Blueair Blue Pure 211i Max Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Why GLP-1 Labels Are Changing
GLP-1 RAs mimic the effects of the natural hormone glucagon-like peptide-1, which is released by the intestine. The hormone helps lower blood glucose after eating and acts in parts of the brain involved in appetite and food intake. These medicines are used for diabetes and weight-management purposes.
The FDA describes NAION as a rare condition caused by decreased blood flow to the optic nerve’s front portion, known as the optic disc. It says the underlying cause is not completely understood. Potential risk factors listed in the communication include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. The alert does not say that these factors establish whether a particular patient will develop NAION.
The agency’s action is a labeling requirement for medication application holders, not a statement in the supplied communication that GLP-1 RAs have been withdrawn or that patients generally should discontinue them. The FDA frames the issue as a potential increased risk and provides separate advice for patients and clinicians on symptoms and follow-up.
Risk Level and Individual Cases
The FDA communication describes a potential increased risk; it does not provide, in the supplied material, a numerical estimate of the risk, the number of cases considered, or a comparison with people not taking GLP-1 RAs. The notice also does not establish that a medication caused NAION in any particular patient. Those details are not stated in the source material provided here.
The FDA says NAION’s underlying cause is not completely understood, and the listed risk factors do not determine who will develop it. The communication does not specify when revised labels will appear for each product or provide product-by-product implementation dates. Patients with symptoms or a history of NAION should discuss their own treatment choices with a health professional rather than make changes based only on the alert.
Label Updates and Clinical Follow-Up
Application holders for GLP-1 RA medications are required to add the NAION information to the Warnings and Precautions section of labeling. The FDA communication supplied for this report does not give a timetable for when each revised label will be published. Patients and clinicians can check the current prescribing information for a specific medication as updates are issued.
For patients taking these medicines, the immediate practical step is to report sudden, painless vision loss in one eye or other new visual disturbances promptly. Clinicians should arrange ophthalmology evaluation if NAION is suspected and consider whether treatment should continue if the diagnosis is made, weighing benefits against risk. The FDA’s alert does not direct all users to stop GLP-1 RA treatment.
Key Questions
What safety change is the FDA requiring?
The FDA is requiring application holders for all GLP-1 RA medications to add information about a potential increased risk of NAION to the Warnings and Precautions section of labeling.
What is NAION?
NAION is a rare condition involving decreased blood flow to the front part of the optic nerve. The FDA says it can cause acute, painless decreased vision in one eye, including permanent vision loss.
Which symptoms should prompt a call to a health professional?
Contact a health professional right away for sudden, painless vision loss in one eye, blind spots or tunnel vision, color distortion, or hazy or blurry areas that reduce central sharpness. The FDA says the loss may be noticed on waking.
Should patients stop taking their GLP-1 medication?
The FDA communication does not advise all patients to stop treatment. Anyone who has had a NAION event should discuss whether to continue or stop the medication with a health professional. Clinicians are advised to consider discontinuation after NAION unless treatment benefits clearly outweigh the risk.
Does the alert give an estimate of how likely NAION is?
No numerical risk estimate or comparison baseline is included in the supplied FDA material. The agency describes the condition as rare and the association as a potential increased risk.
Source: fda.gov
